Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) has appointed Santiago Arroyo, M.D., Ph.D., as Chief Development Officer effective March 31. Dr. Arroyo brings over 20 years of experience, having previously served as Chief Medical Officer at Momenta Pharmaceuticals. He will oversee the clinical development of Bicycle’s expanding pipeline, including programs in oncology. Jennifer Perry, Pharm.D., has been promoted to Senior Vice President, Commercial, with over 15 years of experience in oncology. The transition includes the departure of Chief Medical Officer Dr. Dominic Smethurst. These leadership changes aim to position Bicycle for continued growth and success in late-stage development.
Bicycle Therapeutics has announced a strategic collaboration with Novartis to develop targeted radioligand therapies for oncology. Under this agreement, Bicycle will receive a
Bicycle Therapeutics (NASDAQ: BCYC) announced participation in two investor conferences in March 2023. The company will host a fireside chat at Cowen's 43rd Annual Health Care Conference on March 7 at 9:50 a.m. ET, and at the Barclays Global Healthcare Conference on March 16 at 9:00 a.m. ET. Live webcasts of these discussions will be available on the company's website, with archived replays accessible for 90 days post-event. Bicycle Therapeutics specializes in developing a new class of therapeutics using its proprietary Bicycle technology, targeting underserved diseases with high-affinity and selectivity.
Bicycle Therapeutics (NASDAQ: BCYC) reported fourth-quarter and full-year 2022 results, highlighting significant progress with advanced clinical trials for BT8009, BT5528, and BT7480. BT8009 received Fast Track Designation from the FDA, and Phase I results showed anti-tumor activity in treated patients. The company has a cash position of $339.2 million, expected to support operations into 2025. R&D expenses rose to $81.6 million in 2022, leading to a net loss of $112.7 million, or $(3.80) per share. Further updates on trials are anticipated by the end of 2023, positioning the company for future milestones.
Bicycle Therapeutics (NASDAQ: BCYC) announced promising results from the Phase I trial of BT8009, a novel BTC targeting Nectin-4, showing a 50% overall response rate and a 75% clinical benefit rate in urothelial cancer. A complete response was recorded at the 5 mg/m² dose. As of
Bicycle Therapeutics plc (NASDAQ:BCYC), a pioneering biotechnology firm, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 9:20 a.m. ET. This event will be held virtually, and a live webcast will be accessible on their website, www.bicycletherapeutics.com. The archived version of the chat will be available for 90 days. Bicycle Therapeutics specializes in developing novel therapeutics, called Bicycles, which are designed for diseases lacking effective treatments. Their ongoing clinical trials include BT5528, BT8009, BT7480, and BT1718, targeting various significant tumor antigens.
The report titled "Non-Viral / Intracellular Drug Delivery Systems Market" by ResearchAndMarkets.com highlights the rising demand for efficient drug delivery systems in the biopharmaceutical industry. It notes that over 20% of the proteome resides within cell membranes, necessitating innovative delivery methods for therapeutic intervention. Key advancements include non-viral systems such as exosome-based techniques and cell-penetrating peptides. The report reveals that around 1,300 patents have been filed, indicating substantial innovation, with over 20,000 studies on oligonucleotide-based therapeutics underway. The market is expected to grow significantly in the near term.
Nerviano Medical Sciences announced the appointment of Terrence West as New Business, Virtual CEO, tasked with enhancing the value of its oncology drug asset NMS-173. With over 25 years in biopharma and expertise in drug development, West aims to strategically position NMS-173, a dual IDH1/IDH2 inhibitor, against current cancer therapies. The drug shows promise in overcoming resistance mechanisms and has demonstrated significant anti-tumor activity. This leadership move reflects Nerviano's intent to strengthen its presence in the Boston biotech market.
Bicycle Therapeutics plc (NASDAQ: BCYC) will present results from its Phase I/II trial of BT8009 at the 2023 ASCO GU Cancers Symposium, taking place in San Francisco from February 16-18, 2023. The conference call, scheduled for February 14 at 8:00 a.m. ET, will feature Dr. Capucine Baldini and Dr. Daniel Petrylak discussing the data on BT8009, a BTC targeting Nectin-4. The poster presentation, under the title 'BT8009-100,' will occur on February 17. Bicycle Therapeutics specializes in innovative therapies, focusing on advanced malignancies.
Bicycle Therapeutics (NASDAQ:BCYC) announced the FDA's grant of Fast Track Designation for its BT8009 monotherapy targeting urothelial cancer. This designation aims to expedite the development of therapies addressing serious unmet medical needs. CEO Kevin Lee highlighted the importance of this FTD for aligning with the FDA to meet patient needs. Fast Track programs can benefit from more frequent FDA interactions and may qualify for Accelerated Approval and Priority Review if criteria are met, indicating progress in BT8009’s development.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
